Ultragenyx Pharmaceutical Inc
Clinical trials sponsored by Ultragenyx Pharmaceutical Inc, explained in plain language.
Biopharmaceutical company developing treatments for rare and ultra-rare diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug aims to strengthen bones in kids with rare brittle bone disease Results expected Jan 2027 (estimated) May already have reported ↗ 🚀 Make-or-break
- Gene therapy for sanfilippo a: does it last? Results expected Aug 2027 (estimated)
- New oil therapy could slash Life-Threatening events in kids with rare metabolic disease Results expected Aug 2027 (estimated)
- Gene therapy aims to tame rare metabolic disorder Results expected Sep 2027 (estimated)
-
Gene therapy could free GSD ia patients from constant cornstarch
Disease control CompletedThis Phase 3 trial tested a gene therapy called DTX401 in 49 people with glycogen storage disease type Ia (GSD Ia). The goal was to see if a single infusion could reduce or eliminate the need for frequent cornstarch doses to keep blood sugar stable. Participants were randomly ass…
Phase 3 • Sponsor: Ultragenyx Pharmaceutical Inc • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Gene therapy for rare Sugar-Storage disease shows promise in Long-Term safety check
Disease control CompletedThis study checked the long-term safety of a one-time gene therapy (DTX401) in 12 adults with glycogen storage disease type Ia, a rare condition that causes dangerously low blood sugar. Researchers monitored side effects and how well the therapy helped control blood sugar levels …
Sponsor: Ultragenyx Pharmaceutical Inc • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New angelman drug shows promise in early safety trial
Disease control CompletedThis study tested a new medicine called GTX-102 in 74 children with Angelman Syndrome, a rare genetic disorder causing developmental delays and seizures. The main goal was to see if the drug is safe and tolerable when given as a spinal injection. Researchers monitored side effect…
Phase 1/2 • Sponsor: Ultragenyx Pharmaceutical Inc • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC